查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1466438

隐球菌病市场：依治疗方法、通路分类 - 全球预测 2024-2030

Cryptococcosis Market by Treatment (Amphotericin B, Fluconazole, Flucytosine), Distribution Channel (Hospital Pharmacies, Mail Order Pharmacies, Retail Pharmacies & Drug Stores) - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年隐球菌病市场规模为59.1亿美元，预计2024年将达63.5亿美元，2030年将达到99亿美元，复合年增长率为7.64%。

隐球菌病市场包括涉及隐球菌病预防、诊断、治疗和管理的各种药物、服务和活动。这包括行销专门用于治疗隐球菌病的抗真菌药物，隐球菌病是一种由隐球菌属引起的真菌感染疾病，主要影响肺部和中枢神经系统。隐球菌病市场的主要应用是药物治疗和诊断测试。爱滋病毒/爱滋病和其他削弱免疫力的疾病的增加是推动隐球菌病治疗药物需求的主要因素。诊断技术的进步使得能够及早、准确地识别感染疾病，增加了对治疗药物的需求。世界各地（尤其是新兴国家）医疗保健基础设施的扩张也支持了市场开拓。新兴经济体开拓的市场以及抗真菌抗药性管理和个人化医疗方法的进一步开拓存在潜在机会。儘管存在这些成长要素，但抗真菌治疗的高昂费用限制了一些患者获得治疗的机会。人们越来越担心抗真菌抗药性会降低现有治疗方法的有效性。此外，一些地区的医疗基础设施薄弱可能会阻碍先进治疗和诊断的引入。药物审批的监管障碍和新型抗真菌化合物的管道有限也影响了市场潜力。新型药物输送系统（例如奈米颗粒和标靶药物输送）的进步有可能显着提高现有治疗方法的疗效。替代疗法（例如免疫疗法和联合治疗）的研究也可能导致这种疾病的治疗取得突破。最后，开发快速、灵敏且具成本效益的诊断测试对于早期发现和早期治疗至关重要。

主要市场统计
基准年[2023] 59.1亿美元
预测年份 [2024] 63.5亿美元
预测年份 [2030] 99亿美元
复合年增长率（%） 7.64%

治疗Amphotericin B主要用于治疗显着的隐球菌病病例。

Amphotericin B是一种强效抗真菌药物，常被用作重症隐球菌病、尤其是隐球菌脑膜炎的第一线治疗药物。由于口服生物利用度较低，通常静脉注射。Amphotericin B与麦角固醇（真菌细胞膜的主要成分）结合，形成孔洞并杀死细胞。然而，严重的副作用，如肾毒性（肾损伤）、发烧、发冷和贫血可能会限制其使用，并且在治疗期间必须进行监测。Fluconazole是一种三唑类抗真菌药物，用于治疗各种型态的隐球菌感染疾病并作为预防疾病復发的维持治疗。这是一种有利的治疗选择，因为它可以口服给药并且具有良好的安全性。Fluconazole透过抑制真菌细胞色素 P450 酶羊毛甾醇 14-a-脱甲基酶（麦角甾醇合成所需）来发挥作用，从而抑制真菌细胞膜的合成。儘管Fluconazole有效，但它可能会产生抗药性，尤其是长期使用。Flucytosine又称5-氟胞嘧啶，是抗真菌药物，由于其协同效应，常与Amphotericin B联合用于治疗隐球菌病。该药物在真菌细胞中转化为 5-Fluorouracil，抑制 DNA 和 RNA 合成并导致细胞死亡。儘管Flucytosine通常耐受性良好，但它具有骨髓抑制和胃肠道不适等副作用。由于可能会产生对Flucytosine的抗药性，因此其使用通常仅限于在仔细的医疗监督下联合治疗。

通路零售药局是轻鬆快速取得隐球菌病药物的好选择。

隐球菌病药物透过多种管道分发，以确保患者能够获得。医院药局是隐球菌病药物的主要通路。住院患者通常在这里接受初步治疗，尤其是感染疾病严重的患者。医院药局维持重要抗真菌药物（如Amphotericin B和Flucytosine）的供应，并确保及时给药，作为医院护理的一部分。这些设施对于急性管理和在门诊环境中启动持续治疗方法至关重要。通讯药局为出院后治疗隐球菌病的患者或正在进行长期治疗计划的患者提供了一种方便且通常节省成本的方法。这种通路有利于需要稳定药物供应的患者，并增加了送货上门的便利性。通讯服务对于居住在偏远地区或行动不便的患者尤其有利。零售药局和药局是购买门诊病人药物的便利场所。这些商店对于需要快速处方笺和续药的患者至关重要，并且它们提供广泛的地理覆盖范围和延长的营业时间。零售药局也提供药事服务和咨询，并在整体疾病管理中发挥重要作用。

区域洞察

在美洲，特别是在美国和加拿大，隐球菌病被认为是一种机会性感染疾病，主要影响免疫力缺乏，例如爱滋病毒/爱滋病患者。儘管广泛的抗逆转滤病毒治疗计划已经降低了隐球菌病的发生率，但它仍然是一个令人担忧的问题。这些国家的客户购买行为倾向于青睐经过 FDA 批准且具有良好有效性记录的既定治疗方法。用于研究隐球菌脑膜炎的研究津贴投入增加，并且重点放在改进诊断技术上。在欧盟国家，消费者对隐球菌病治疗的需求很大程度取决于免疫力缺乏患者群体的病例。欧盟遵循影响购买行为的严格监管准则，并且经证明不仅有效而且具有成本效益的产品通常会受到青睐。欧盟最近的倡议，例如创新药物倡议，支持新治疗方法的研究。中东和非洲地区隐球菌病的发生率差异很大，撒哈拉以南非洲地区的爱滋病毒/爱滋病发病率特别高，造成了重大负担。非洲市场正在寻找负担得起且容易获得的治疗方法，而富裕的中东国家正在转向更新、更先进的治疗方法。非洲针对爱滋病毒/爱滋病的公共卫生努力也在隐球菌病的管理中发挥重要作用。在亚太地区，中国、日本和印度等国家呈现多样化的市场动态。亚太地区的抗真菌药物专利也在增加，当地製药公司寻求满足该地区的需求。

FPNV定位矩阵

FPNV定位矩阵对于评估隐球菌病市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对隐球菌病市场供应商的现状进行深入而详细的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

该报告对以下几个方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4. 竞争评估和情报：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况和製造能力进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1. 隐球菌病市场的市场规模和预测是多少？

2.在隐球菌病市场预测期间内，有哪些产品、细分市场、应用和领域需要考虑投资？

3.隐球菌市场的技术趋势和法规结构是什么？

4.隐球菌病市场主要供应商的市场占有率是多少？

5. 进入隐球菌市场合适的型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 感染疾病和致命真菌病的盛行率增加
      • 与爱滋病毒/爱滋病隐球菌病相关的新发现
      • 提高学名药和成药的供应
    • 抑制因素
      • 患者临床治疗意识的局限性
      • 由于感染患者死亡率增加，检测和诊断范围缩小
    • 机会
      • 政府首选计划开发隐球菌脑膜炎的有效治疗方法
      • 隐球菌病药物开发的增加和临床试验生态系统的演变
    • 任务
      • 与使用隐球菌病药物相关的副作用
      • 由于製药公司无法满足需求，药物开发计画资金不足
  • 市场区隔分析
    • 治疗：Amphotericin B主要用于治疗严重的隐球菌病病例。
    • 分销管道：零售药局是轻鬆快速取得隐球菌病药物的好选择。
  • 市场趋势分析
  • 俄罗斯-乌克兰衝突的累积影响
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法规结构分析
  • 客户客製化

第六章 隐球菌病市场（依治疗）

  • 两性霉素B
  • Fluconazole
  • Flucytosine

第七章 隐球菌病市场：按分销管道

  • 医院药房
  • 通讯药房
  • 零售药局/药局

第八章美洲隐球菌病市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区隐球菌病市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章 欧洲、中东和非洲的隐球菌病市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Astellas来製药完成对 Propeller Therapeutics 的收购
    • 诺华透过收购 DTx Pharma 加强神经科学产品线和 xRNA 平台能力
    • 葛兰素史克同意收购后期生物製药公司 BELLUS Health

第12章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-4348D129F9A0

[183 Pages Report] The Cryptococcosis Market size was estimated at USD 5.91 billion in 2023 and expected to reach USD 6.35 billion in 2024, at a CAGR 7.64% to reach USD 9.90 billion by 2030.

The Cryptococcosis market encompasses a range of pharmaceutical products, services, and activities involved in the prevention, diagnosis, treatment, and management of Cryptococcosis. It includes the sales of antifungal drugs specifically used to treat Cryptococcosis, a fungal infection caused by Cryptococcus species, which primarily affects the lungs and central nervous system. The primary applications of the Cryptococcosis market involve pharmaceutical therapies and diagnostic testing. An increasing rate of HIV/AIDS and other conditions leading to compromised immune systems contribute significantly to generating need for the Cryptococcosis medication. Advancements in diagnostic technologies allow for early and precise identification of the infection, thus propelling the demand for treatments. Expansion in healthcare infrastructure globally, especially in the developing countries, also foster's market growth. Potential opportunities exist in the untapped markets of emerging economies and in the further development of antifungal resistance management and personalized medicine approaches. Despite the growth factors, high costs associated with antifungal therapy can limit accessibility for some patients; there is also a growing concern over antifungal resistance which reduces the efficacy of existing treatments. Furthermore, poor healthcare infrastructure in some regions can impede the adoption of advanced therapeutics and diagnostics. Regulatory hurdles for drug approval and the limited pipeline of novel antifungal compounds also affect market potential. Advances in novel drug delivery systems, such as nanoparticle and targeted drug delivery, could greatly improve the efficacy of existing treatments. Research into alternative treatments, such as immunotherapies or combination therapies, could also offer breakthroughs in the management of the disease. Lastly, the development of rapid, sensitive, and cost-effective diagnostic tests is essential for early detection and treatment.

KEY MARKET STATISTICS
Base Year [2023] USD 5.91 billion
Estimated Year [2024] USD 6.35 billion
Forecast Year [2030] USD 9.90 billion
CAGR (%) 7.64%

Treatment: Amphotericin B primarily and significantly used to treat the vital cases of cryptococcosis

Amphotericin B is a powerful antifungal medication often used as a primary treatment for severe cases of cryptococcosis, particularly cryptococcal meningitis. It is typically administered intravenously due to its poor oral bioavailability. Amphotericin B binds to ergosterol, a key component of fungal cell membranes, creating pores that lead to the cell's death. However, its use can be limited by significant side effects including nephrotoxicity (kidney damage), fever, chills, and anemia, therefore, monitoring is necessary during treatment. Fluconazole is a triazole antifungal medication used as a treatment for various forms of cryptococcal infections and as maintenance therapy to prevent recurrence of the disease. It is an advantageous treatment option due to its oral administration and favorable safety profile. Fluconazole works by inhibiting the fungal cytochrome P450 enzyme lanosterol 14-a-demethylase, which is required for the synthesis of ergosterol, thus disrupting fungal cell membrane synthesis. Despite its effectiveness, fluconazole resistance can occur, especially with prolonged use. Flucytosine, also known as 5-fluorocytosine, is an antifungal medication that is often used in combination with Amphotericin B for the treatment of cryptococcosis due to its synergistic effects. The drug is converted within fungal cells into 5-fluorouracil, which inhibits DNA and RNA synthesis, leading to cell death. Flucytosine is generally well-tolerated but can have side effects such as bone marrow suppression and gastrointestinal upset. Resistance to flucytosine can develop, and thus its use is typically reserved for combination therapy under careful medical supervision.

Distribution Channel: Retail pharmacies are good option for easy and quick availability of cryptococcosis medications

Cryptococcosis medications are distributed through various channels to ensure availability for patients. Hospital pharmacies represent a principal distribution channel for cryptococcosis medications. Hospitalized patients often receive their initial treatment in this setting, particularly if the infection is severe. Hospital pharmacies maintain a supply of crucial antifungals such as Amphotericin B and Flucytosine and ensure timely administration as part of inpatient care. These facilities are essential for acute management and for initiating treatment regimens that may be continued on an outpatient basis. Mail order pharmacies offer a convenient and often cost-saving avenue for patients managing cryptococcosis post-discharge or for those under long-term treatment plans. This distribution channel is beneficial for patients requiring consistent medication supplies with the added convenience of home delivery. Mail order services can be particularly advantageous for those living in remote areas or for patients with limited mobility. Retail pharmacies and drug stores serve as an accessible point of purchase for outpatient cryptococcosis medications. These establishments are crucial for patients who may need to fill or refill prescriptions rapidly, offering widespread geographic coverage and extended operating hours. Retail pharmacies also provide pharmaceutical care and counsel, playing a significant role in the overall management of the condition.

Regional Insights

In the Americas, particularly in the United States and Canada, cryptococcosis is considered an opportunistic infection predominantly affecting immunocompromised individuals, such as those with HIV/AIDS. Large-scale antiretroviral treatment programs have helped reduce the incidence of cryptococcosis, but it remains a concern. Customer purchasing behavior in these nations tends to prioritize well-established, FDA-approved treatments with a proven track record of efficacy. There has been an increase in investment towards research grants for studying cryptococcal meningitis, as well as a focus on improved diagnostic techniques. In EU countries, the consumer need for cryptococcosis treatments is largely driven by cases among immunocompromised patient populations. The EU follows stringent regulatory guidelines which influence purchasing behavior, often favoring products that have demonstrated not only efficacy but also cost-effectiveness. Recent EU initiatives, such as the Innovative Medicines Initiative, have supported research into new treatments. The MEA region exhibits a wide disparity in the incidence of cryptococcosis, with Sub-Saharan Africa bearing a significant burden due to high rates of HIV/AIDS. There is a clear need for affordable and accessible treatments within African markets, while wealthier Middle Eastern nations may focus on newer and more advanced therapy options. Public health initiatives aimed at HIV/AIDS in Africa also play a crucial role in the management of cryptococcosis. In the Asia Pacific, countries such as China, Japan, and India present diverse market dynamics. The Asia Pacific region is also seeing an uptick in patents related to antifungal medications, driven by local pharmaceutical companies seeking to address the regional needs.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Cryptococcosis Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cryptococcosis Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Cryptococcosis Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Astellas Pharma Inc., B.M. Pharmaceuticals, Bausch Health Companies Inc., Bayer AG, Bristol-Myers Squibb Company, Citron Pharma, Eisai Co., Ltd., Gilead Sciences, Inc., GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Johnson & Johnson Services, Inc., Jolly Limited, Lunan Pharmaceutical Group, Matinas Biopharma Holdings, Inc., Merck & Co., Inc., Novartis AG, NuCare Pharmaceuticals, Inc., Pfizer Inc., Sanofi S.A., Sigmapharm Laboratories, LLC, Skyepharma Production SAS, Sumitomo Pharma Co., Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Cryptococcosis Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Treatment
    • Amphotericin B
    • Fluconazole
    • Flucytosine
  • Distribution Channel
    • Hospital Pharmacies
    • Mail Order Pharmacies
    • Retail Pharmacies & Drug Stores
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Cryptococcosis Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cryptococcosis Market?

3. What are the technology trends and regulatory frameworks in the Cryptococcosis Market?

4. What is the market share of the leading vendors in the Cryptococcosis Market?

5. Which modes and strategic moves are suitable for entering the Cryptococcosis Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing Prevalence of Infectious Diseases and Fatal Fungal Disease
      • 5.1.1.2. Rising Insights into HIV/AIDS-Associated Cryptococcosis
      • 5.1.1.3. Increasing Availability of Generic and Over-the-Counter Medicine
    • 5.1.2. Restraints
      • 5.1.2.1. Limited Clinical Awareness in Patients Regarding Treatments
      • 5.1.2.2. Reduced Scope of Testing and Diagnostics due to Increased Mortality Among Cryptococcosis Infected Patients
    • 5.1.3. Opportunities
      • 5.1.3.1. Favorable Government Programs for the Development of Effective Therapeutics for Cryptococcal Meningitis Disease
      • 5.1.3.2. Increasing Drug Development and Evolving Clinical Trial Ecosystem for Cryptococcosis
    • 5.1.4. Challenges
      • 5.1.4.1. Side Effects Associated with The Usage of Cryptococcosis Drugs
      • 5.1.4.2. Pharmaceutical Companies Failing to Address The Need and Poorly Funded Drug Development Programs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment: Amphotericin B primarily and significantly used to treat the vital cases of cryptococcosis
    • 5.2.2. Distribution Channel: Retail pharmacies are good option for easy and quick availability of cryptococcosis medications
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework Analysis
  • 5.9. Client Customization

6. Cryptococcosis Market, by Treatment

  • 6.1. Introduction
  • 6.2. Amphotericin B
  • 6.3. Fluconazole
  • 6.4. Flucytosine

7. Cryptococcosis Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Hospital Pharmacies
  • 7.3. Mail Order Pharmacies
  • 7.4. Retail Pharmacies & Drug Stores

8. Americas Cryptococcosis Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Cryptococcosis Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Cryptococcosis Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. Astellas Completes Acquisition of Propella Therapeutics
    • 11.3.2. Novartis Builds on Neuroscience Pipeline and xRNA Platform Capabilities with Acquisition of DTx Pharma
    • 11.3.3. GSK Reaches Agreement to Acquire Late-stage Biopharmaceutical Company BELLUS Health

12. Competitive Portfolio

  • 12.1. Key Company Profiles
  • 12.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. CRYPTOCOCCOSIS MARKET RESEARCH PROCESS
  • FIGURE 2. CRYPTOCOCCOSIS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. CRYPTOCOCCOSIS MARKET DYNAMICS
  • FIGURE 7. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. CRYPTOCOCCOSIS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 20. CRYPTOCOCCOSIS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CRYPTOCOCCOSIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY AMPHOTERICIN B, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY AMPHOTERICIN B, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY FLUCONAZOLE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY FLUCONAZOLE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY FLUCYTOSINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY FLUCYTOSINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY MAIL ORDER PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY MAIL ORDER PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY RETAIL PHARMACIES & DRUG STORES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY RETAIL PHARMACIES & DRUG STORES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 24. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 25. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 26. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 27. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 28. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 29. ARGENTINA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 30. ARGENTINA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 31. ARGENTINA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 32. ARGENTINA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 33. BRAZIL CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 34. BRAZIL CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 35. BRAZIL CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 36. BRAZIL CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 37. CANADA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 38. CANADA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 39. CANADA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 40. CANADA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 41. MEXICO CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 42. MEXICO CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 43. MEXICO CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 44. MEXICO CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 45. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 46. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 47. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 48. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 49. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 50. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 58. AUSTRALIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 60. AUSTRALIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 61. CHINA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 62. CHINA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 63. CHINA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 64. CHINA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 65. INDIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 66. INDIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 67. INDIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 68. INDIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 69. INDONESIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 70. INDONESIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 71. INDONESIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 72. INDONESIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 73. JAPAN CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 74. JAPAN CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 75. JAPAN CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 76. JAPAN CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 77. MALAYSIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 78. MALAYSIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 79. MALAYSIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 80. MALAYSIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 82. PHILIPPINES CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 84. PHILIPPINES CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 85. SINGAPORE CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 86. SINGAPORE CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 87. SINGAPORE CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 88. SINGAPORE CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 90. SOUTH KOREA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 92. SOUTH KOREA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 93. TAIWAN CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 94. TAIWAN CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 95. TAIWAN CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 96. TAIWAN CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 97. THAILAND CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 98. THAILAND CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 99. THAILAND CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 100. THAILAND CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 101. VIETNAM CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 102. VIETNAM CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 103. VIETNAM CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 104. VIETNAM CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 111. DENMARK CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 112. DENMARK CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 113. DENMARK CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 114. DENMARK CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 115. EGYPT CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 116. EGYPT CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 117. EGYPT CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 118. EGYPT CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 119. FINLAND CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 120. FINLAND CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 121. FINLAND CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 122. FINLAND CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 123. FRANCE CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 124. FRANCE CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 125. FRANCE CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 126. FRANCE CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 127. GERMANY CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 128. GERMANY CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 129. GERMANY CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 130. GERMANY CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 131. ISRAEL CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 132. ISRAEL CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 133. ISRAEL CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 134. ISRAEL CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 135. ITALY CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 136. ITALY CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 137. ITALY CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 138. ITALY CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 140. NETHERLANDS CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 142. NETHERLANDS CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 143. NIGERIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 144. NIGERIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 145. NIGERIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 146. NIGERIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 147. NORWAY CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 148. NORWAY CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 149. NORWAY CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 150. NORWAY CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 151. POLAND CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 152. POLAND CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 153. POLAND CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 154. POLAND CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 155. QATAR CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 156. QATAR CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 157. QATAR CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 158. QATAR CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 159. RUSSIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 160. RUSSIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 161. RUSSIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 162. RUSSIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 164. SAUDI ARABIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 166. SAUDI ARABIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 168. SOUTH AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 170. SOUTH AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 171. SPAIN CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 172. SPAIN CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 173. SPAIN CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 174. SPAIN CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 175. SWEDEN CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 176. SWEDEN CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 177. SWEDEN CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 178. SWEDEN CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 180. SWITZERLAND CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 182. SWITZERLAND CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 183. TURKEY CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 184. TURKEY CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 185. TURKEY CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 186. TURKEY CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 192. UNITED KINGDOM CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 194. UNITED KINGDOM CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 195. CRYPTOCOCCOSIS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 196. CRYPTOCOCCOSIS MARKET, FPNV POSITIONING MATRIX, 2023